Vivoryon Therapeutics N.V./€VVY

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V. is a clinical-stage biotechnology company specializing in the development of small molecule medicines targeting post-translational modifications implicated in various diseases. Its lead candidate, varoglutamstat, is an oral inhibitor of glutaminyl cyclases (QPCT and QPCTL) with potential applications in inflammatory and fibrotic diseases, neurodegenerative conditions, and cancer. Originally focused on Alzheimer's disease, the company shifted its strategic emphasis to kidney diseases in 2024 after observing significant improvements in kidney function during clinical trials. Headquartered in Halle (Saale) and Munich, Germany, Vivoryon has expanded its intellectual property portfolio, including a U.S. patent granted in May 2025 for varoglutamstat, providing exclusivity through 2044. The company's unique approach centers on modulating disease-related protein activity and stability through targeted enzyme inhibition.

Ticker

€VVY

Primary listing

AEX

Industry

Biotechnology
Headquarters

Employees

14

VVY Metrics

BasicAdvanced
€38M
-
-€0.79
1.96
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €VVY

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs